A Phase 3 Randomized Controlled Trial of Anifrolumab in Patients with Moderate to Severe Systemic Lupus Erythematosus

被引：0

作者：

Furie, Richard ^{[1
]}

Morand, Eric ^{[2
]}

Bruce, Ian ^{[3
]}

Manzi, Susan ^{[4
]}

Kalunian, Kenneth ^{[5
]}

Vital, Edward ^{[6
]}

Lawrence-Ford, Theresa ^{[7
]}

Gupta, Ramesh ^{[8
]}

Hiepe, Falk ^{[9
]}

Santiago, Mittermayer ^{[10
]}

Brohawn, Philip ^{[11
]}

Berglind, Anna ^{[12
]}

Tummala, Raj ^{[11
]}

机构：

[1] Zucker Sch Med Hofstra Northwell, New York, NY USA

[2] Monash Univ, Melbourne, Vic, Australia

[3] Univ Manchester, Manchester, Lancs, England

[4] Allegheny Hlth Network, Pittsburgh, PA USA

[5] Univ Calif San Diego, Div Rheumatol Allergy & Immunol, La Jolla, CA 92093 USA

[6] Univ Leeds, Leeds, W Yorkshire, England

[7] North Georgia Rheumatol, Lawrenceville, GA USA

[8] Baptist Mem Hosp, Memphis, TN 38146 USA

[9] Charite, Berlin, Germany

[10] Bahiana Sch Med & Publ Hlth, Salvador, BA, Brazil

[11] AstraZeneca, Gaithersburg, MD USA

[12] AstraZeneca, Gothenburg, Sweden

来源：

ARTHRITIS & RHEUMATOLOGY | 2019年 / 71卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

1763

引用

页数：3

共 50 条

[21] ANIFROLUMAB REDUCES DISEASE ACTIVITY IN MULTIPLE ORGAN DOMAINS IN MODERATE TO SEVERE SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Merrill, J. T.
Furie, R.
Werth, V. P.
Khamashta, M.
Drappa, J.
Wang, L.
Illei, G.
[J]. ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 293 - 293
[22] Anifrolumab for refractory lupus erythematosus panniculitis in systemic lupus erythematosus
Maeshima, Keisuke
Abe, Tasuku
Imada, Chiharu
Ozaki, Takashi
Shibata, Hirotaka
[J]. RHEUMATOLOGY, 2024, 63 (03) : e115 - e117
[23] Efficacy and Safety of Epratuzumab in Patients with Moderate-to-Severe Systemic Lupus Erythematosus: Results from Two Phase 3 Randomized, Placebo-Controlled Trials
Clowse, Megan E. B.
Wallace, Daniel J.
Furie, Richard
Petri, Michelle
Pike, Marilyn
Leszczynski, Piotr
Neuwelt, C. Michael
Hobbs, Kathryn
Keiserman, Mauro
Duca, Liliana
Kalunian, Kenneth
Bongardt, Sabine
Stach, Christian
Beaudot, Carolyn
Kilgallen, Brian
Galateanu, Catrinel
Gordon, Caroline
[J]. ARTHRITIS & RHEUMATOLOGY, 2015, 67
[24] Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1) a randomised, controlled, phase 3 trial
Furie, Richard A.
Morand, Eric F.
Bruce, Ian N.
Manzi, Susan
Kalunian, Kenneth C.
Vital, Edward M.
Ford, Theresa Lawrence
Gupta, Ramesh
Hiepe, Falk
Santiago, Mittermayer
Brohawn, Philip Z.
Berglind, Anna
Tummala, Raj
[J]. LANCET RHEUMATOLOGY, 2019, 1 (04): : E208 - E219
[25] Anifrolumab (Saphnelo) for Systemic Lupus Erythematosus
不详
[J]. MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2021, 63 (1633): : 146 - 147
[26] Anifrolumab for the treatment of active systemic lupus erythematosus: a meta-analysis of randomized controlled trials
Lee, Y. H.
Song, G. G.
[J]. ZEITSCHRIFT FUR RHEUMATOLOGIE, 2021, 80 (10): : 988 - 994
[27] Raloxifene for postmenopausal patients with systemic lupus erythematosus (SLE): A randomized controlled trial
Mok, CC
Mak, A
To, CH
Ma, KM
[J]. ARTHRITIS AND RHEUMATISM, 2005, 52 (09): : S196 - S197
[28] Multidisciplinary care in patients with systemic lupus erythematosus: a randomized controlled trial in China
Le Zhang
Shikai Geng
Liping Qian
Shuang Ye
Xiaodong Wang
Guohong Lu
Yang Ding
Ting Li
[J]. International Journal of Clinical Pharmacy, 2019, 41 : 1247 - 1255
[29] Multidisciplinary care in patients with systemic lupus erythematosus: a randomized controlled trial in China
Zhang, Le
Geng, Shikai
Qian, Liping
Ye, Shuang
Wang, Xiaodong
Lu, Guohong
Ding, Yang
Li, Ting
[J]. INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2019, 41 (05) : 1247 - 1255
[30] Systemic Lupus Erythematosus Responder Index Assessment of Responders in EMBLEM, a Phase IIb Study in Patients with Moderate to Severe Systemic Lupus Erythematosus
Petri, Michelle
Pike, Marilyn C.
Kelley, Lexy
Kilgallen, Brian
Gordon, Caroline
[J]. ARTHRITIS AND RHEUMATISM, 2011, 63 (10): : S539 - S539

← 1 2 3 4 5 →